162 related articles for article (PubMed ID: 35978004)
1. The influence of thyroid hormone medication on intra-therapeutic half-life of
Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
[TBL] [Abstract][Full Text] [Related]
2. The influence of thionamides on intra-thyroidal uptake of
Happel C; Bockisch B; Leonhäuser B; Sabet A; Grünwald F; Groener D
Sci Rep; 2023 Dec; 13(1):21190. PubMed ID: 38040820
[TBL] [Abstract][Full Text] [Related]
3. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of
Happel C; Kranert WT; Gröner D; Baumgarten J; Halstenberg J; Bockisch B; Sabet A; Grünwald F
Endocrine; 2021 Jul; 73(1):125-130. PubMed ID: 33439464
[TBL] [Abstract][Full Text] [Related]
4. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.
Happel C; Kranert WT; Ackermann H; Binse I; Bockisch B; Gröner D; Herrmann K; Grünwald F
Endocrine; 2019 Mar; 63(3):537-544. PubMed ID: 30599051
[TBL] [Abstract][Full Text] [Related]
5. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
7. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
[TBL] [Abstract][Full Text] [Related]
8. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
Larsen PR
J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
[TBL] [Abstract][Full Text] [Related]
9. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
10. Minimally invasive local ablative therapies in combination with radioiodine therapy in benign thyroid disease: preparation, feasibility and efficiency - preliminary results.
Mader A; Mader OM; Gröner D; Korkusuz Y; Ahmad S; Grünwald F; Kranert WT; Happel C
Int J Hyperthermia; 2017 Dec; 33(8):895-904. PubMed ID: 28540810
[TBL] [Abstract][Full Text] [Related]
11. Fixed 30 mCi (1110 MBq)
Pereira LSB; Riguetto CM; Neto AM; Tambascia MA; Ramos CD; Zantut-Wittmann DE
World J Nucl Med; 2021; 20(4):349-354. PubMed ID: 35018149
[TBL] [Abstract][Full Text] [Related]
12. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G
Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994
[TBL] [Abstract][Full Text] [Related]
13. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
Moka D; Voth E; Schicha H
Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
[TBL] [Abstract][Full Text] [Related]
14. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
[TBL] [Abstract][Full Text] [Related]
16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
Yu F; Zhang R; Zhang G; Meng Z; Liu X; He Y; Tan J; Wang R
Med Sci Monit; 2021 Jan; 27():e928796. PubMed ID: 33497370
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studeis on the regulatory system of thyroid hormone secretion and serum triiodothyronine. Part III. Studies on thyroid hormone change and its relationship when TSH in cases with subclinical hypothyroidism (Hashimoto's thyroiditis and 131I treated Graves' disease)].
Takeda Y
Nihon Naibunpi Gakkai Zasshi; 1975 Feb; 51(2):85-97. PubMed ID: 808432
[TBL] [Abstract][Full Text] [Related]
19. The thyroidal T4/T3 ratio and its regulation in non-toxic goitre.
Reinwein D; Durrer HA; Wiermann H; Löhnert J; von zur Mühlen A
Horm Metab Res; 1976 Sep; 8(5):394-9. PubMed ID: 824192
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 99mTc-methoxyisobutyl isonitrile and 201T1 scintigraphy in visualization of suppressed thyroid tissue.
Erdil TY; Onsel C; Kanmaz B; Caner B; Sönmezoğlu K; Ciftçi I; Turoğlu T; Kabasakal L; Sayman HB; Uslu I
J Nucl Med; 2000 Jul; 41(7):1163-7. PubMed ID: 10914905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
